Better Stock Today Challenge: Gilead vs. Kinder Morgan Partners

Image may be NSFW.
Clik here to view.

Bracket showing companies that advanced from the group stages

Motley Fool health care analyst David Williamson makes the case for Gilead Sciences to win this match up. He believes Gilead's Sovaldi will continue to beat analyst estimates and that its runaway success will continue. Estimated to do $1.4 billion in first quarter sales, the instant blockbuster clocked in at $2.3 billion. Gilead already has an even better combo treatment in the works and despite its high price tag, Gilead's future rivals don't appear willing to undercut its cost. With an estimated 150 million hepatitis-c cases worldwide, curing the disease will prove beneficial to humanity and Gilead shareholders.

Joel South, energy analyst at The Motley Fool, thinks Kinder Morgan Partners  is the better investment because the firm is the premier midstream MLP in the world. Kinder Morgan Partners offer a substantial 7.1% distribution yield, but more importantly, the large pipeline operator continues to grow its payments by strict capital discipline and structuring its contracts so 93% of all revenue is absent commodity risk. With $641 billion expected to be spent in the North American midstream market in the next 20 years, Kinder Morgan Partners could outperform the broad market year in and year out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.